Replies to post #766925 on NorthWest Biotherapeutics Inc (NWBO)

[2B_unknown]

ex,

"No, the title is "Medicines Not Reimbursed Through National Prices and Commisioned by NHS England/CDF/IDF".
That says it is has not been commissioned (AKA, funded)."


Maybe so, but a good start...are they waiting for FlaskWorks??


NHS ENGLAND - HIGH COST DRUGS COMMISSIONING LIST
[MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES "AND" COMMISSIONED BY NHS ENGLAND/CDF/IMF] FOR DELEGATED AND RETAINED PRESCRIBED SPECIALISED SERVICES

tbu

[SkyLimit2022]

x,

That’s not what the title means 😶

Simply look at some of the other drugs named on the same spreadsheet—they each have individual funding status & criteria for access…





Murcidencel (DCVax-L) being listed on the NHS “Commissioned by NHS England” High Cost Drugs List does not mean the MAA has been approved. However, it has meaningful implications:

1. Clarifying the Spreadsheet Title

The spreadsheet is titled “Commissioned by NHS England – High Cost Drugs” but this includes both drugs routinely commissioned (fully funded for standard use) and those only accessible through Individual Funding Requests (IFRs). For example:

• Pembrolizumab is on the list and routinely funded for various cancers.

• Murcidencel, by contrast, is only accessible via IFR, meaning NHS clinicians can request it for individual patients under exceptional circumstances.

So the title refers broadly to drugs that NHS England allows to be commissioned in any form—not just those fully recommended.

2. Implication: Recognized, but Not Yet Approved

Murcidencel’s inclusion shows:

• It is recognized by NHS England as a treatment with a viable clinical use.

• A commissioning route (IFR) is available before MHRA approval—typically allowed when data is promising or patient need is high.

This suggests NHS England is:

• Aware of the pending MAA.

• Positioning itself to enable patient access, even before a full decision is made by the MHRA.

3. Possible Post-MAA Pathway

If the MHRA approves the Marketing Authorisation Application:

• Murcidencel could move from IFR-only access to routine commissioning, depending on clinical efficacy, cost-effectiveness, and NICE review.

• Being already on the HCD list makes this transition administratively easier—NHS England is already tracking it.

Summary:

Murcidencel being on the list doesn’t mean it’s approved—but it does mean it’s recognized and accessible via IFR. It also shows NHS England has cleared a preliminary access route, possibly in anticipation of MAA approval.















https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176114523